Literature DB >> 9300350

Pharmacokinetics and pharmacodynamics of azosemide after intravenous and oral administration to rats: absorption from various GI segments.

S H Lee1, M G Lee.   

Abstract

Azosemide, 5, 10, 20, and 30 mg/kg, was administered both intravenously and orally to determine the pharmacokinetics and pharmacodynamics of azosemide in rats (n = 7-12). The absorption of azosemide from various segments of GI tract and the reasons for the appearance of multiple peaks in plasma concentrations of azosemide after oral administration were also investigated. After intravenous (iv) dose, the pharmacokinetic parameters of azosemide such as t1/2. MRT, VSS, CL, CLR, and CLNR were found to be dose-dependent in the dose ranges studied. The percentages of the iv dose excreted in 8-hr urine as azosemide, MI (a metabolite of azosemide), glucuronide of azosemide, and glucuronide of MI-expressed in terms of azosemide-were also dose-dependent in the dose ranges studied. The data above suggest saturable metabolism of azosemide in rats. The measurements taken after the iv administrations such as the 8 hr urine output, the total amount of sodium and chloride excreted in 8-hr urine per 100 g body weight, and diuretic, natriuretic, kaluretic, and chloruretic efficiencies were also shown to be dose-dependent. However, the total amount of potassium excreted in 8-hr urine per 100 g body weight was dose-independent. Similar dose-dependency was also observed following oral administration. Azosemide was absorbed from all regions of GI tract studied and approximately 93.5, 79.1, 86.1, and 71.5% of the doses (5, 10, 20, and 30 mg/kg, respectively) were absorbed between 1 and 24 hr after oral administration. The appearance of multiple peaks after oral administration is suspected to be due mainly to the gastric emptying pattern. The percentages of azosemide absorbed from the GI tract as unchanged azosemide for up to 24 hr after oral doses of 5, 10, 20, and 30 mg/kg were significantly different with doses (decreased with increasing doses), suggesting that the problem of azosemide precipitating in acidic gastric juices or dissolution may have at least partially influenced the absorption of azosemide after oral administration.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9300350     DOI: 10.1007/BF02353480

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  24 in total

1.  [Disposition of azosemide. I. Distribution, metabolism and excretion following intravenous administration to rats].

Authors:  T Asano; T Inoue; M Kurono
Journal:  Yakugaku Zasshi       Date:  1984-11       Impact factor: 0.302

2.  Phase 1 study of azosemide (SK-110): single- and multiple-dose study.

Authors:  F Kuzuya
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1983-01

3.  Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level--time curve.

Authors:  W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

4.  Clinical and pharmacological investigations of the new saluretic azosemid.

Authors:  F Krück; W Bablok; E Besenfelder; G Betzien; B Kaufmann
Journal:  Eur J Clin Pharmacol       Date:  1978-11-27       Impact factor: 2.953

5.  New calculation method for mean apparent drug volume of distribution and application to rational dosage regimens.

Authors:  W L Chiou
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

6.  [Pharmacological studies on azosemide [5-(4'-chloro-5'-sulfamoyl-2'-thenylamino)-phenyltetrazole], a new diuretic (1) Effects on diuresis, plasma renin activity and urinary prostaglandin E excretion in normal rats (author's transl)].

Authors:  Y Suzuki; M Ito; T Komura
Journal:  Nihon Yakurigaku Zasshi       Date:  1982-04

7.  Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism.

Authors:  M G Lee; W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1983-12

8.  Coupling between renal tubular secretion and effect of bumetanide.

Authors:  B Odlind; B Beermann; B Lindström
Journal:  Clin Pharmacol Ther       Date:  1983-12       Impact factor: 6.875

9.  Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous furosemide.

Authors:  T Li; M G Lee; W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1986-10

10.  Pharmacokinetics of drugs in blood II. Unusual distribution and storage effect of furosemide.

Authors:  M G Lee; M L Chen; W L Chiou
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1981-10
View more
  1 in total

1.  Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect.

Authors:  Jee H Shin; Ka Y Choi; Yu C Kim; Myung G Lee
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.